共 50 条
New aspects in the treatment of thyroid cancer. Highlights of the ASCO Annual Meeting 2016
被引:0
|作者:
Loerincz, B. B.
[1
]
Simon, C.
[2
]
Moeckelmann, N.
[1
]
Knecht, R.
[1
]
机构:
[1] Univ Klinikum Hamburg Eppendorf, Univ Klin HNO Heilkunde Kopf Hals Chirurg & Onkol, Martinistr 52, D-20246 Hamburg, Germany
[2] CHU Vaudois, Serv ORL & Chirurg Cervicofaciale, Lausanne, Switzerland
来源:
关键词:
Surgery;
Kinase inhibitors;
Palliative care;
Metastasis;
Thyroid;
PHASE-II;
LENVATINIB;
MEDULLARY;
PAPILLARY;
DTC;
D O I:
10.1007/s00106-016-0246-3
中图分类号:
R76 [耳鼻咽喉科学];
学科分类号:
100213 ;
摘要:
The annual meeting of the American Society of Clinical Oncology (ASCO) took place at the beginning of June 2016 in Chicago. This year a total of 28 studies on the treatment of patients with thyroid cancer were presented, described in this review article according to the degree of cancer cell differentiation. The leading curative treatment modality is still surgery. In contrast, kinase inhibitors are being used increasingly within palliative concepts. The latest state of the art of thyroid cancer treatment, both surgical and medical, is summarized in this review.
引用
收藏
页码:736 / 740
页数:5
相关论文